Renoprotective mechanism of non-steroidal mineralocorticoid receptor antagonist (MRA) – finerenoneReduces inflammation and fibrosis, lowers urinary protein excretion, and delays the progression of kidney disease.Contraindications and administration of finerenoneFinerenone should not be used in patients with serum potassium > 5 mmol/L or eGFR < 25 mL/(min·1.73m²). In patients initiated on a lower dose of finerenone, the […]